At Parthenon Therapeutics, we are reprogramming the tumor microenvironment to beat cancers
Breaking Barriers
To Better Cancer Treatment
Many Cancer Patients Don't Benefit from Existing Therapies – We Lead the Next Generation of Treatment
As our understanding of the mechanisms of cancer resistance has grown, so too have our strategies to combat/address those biological challenges. However, despite recent advances in anti-cancer therapy, many people living with cancer continue to have low response and poor prognosis. Parthenon's approach is informed by our improved understanding of the important role of the tumor microenvironment in fighting disease.
our team
ABOUT our team
We are scientists, drug developers, clinicians, pathologists, bioinformaticians, engineers, innovators, and cancer warriors redefining the treatment landscape for patients with recalcitrant cancers.
Erin joins Parthenon as Manager of Operations. Erin has over ten years of experience in operations and executive administration, specifically in rapidly growing small companies. Her experience and knowledge will allow Parthenon to focus on long term goals; she will manage the physical space, employee experience and all operational tasks.

Erin enjoys everything creative, including interior design. She has remodeled a 1901 Victorian home from digitally designing the floor plans, through the finishes.
Rena joins the tumor immunology team at Parthenon after receiving her PhD from Cold Spring Harbor Laboratory, where she studied T cell exclusion in pancreatic cancer in Douglas Fearon's group. Her research focused on dissecting the dynamic crosstalk among cancer immunogenicity, T cell immunity, and cancer-associated fibroblast heterogeneity. She has been passionate about immunology since examining the role of Notch signaling in T cell development and malignancy in University of Michigan, Ann Arbor. Prior to that, Rena received a MS degree from Wright State University in Dayton, Ohio investigating isoform-specific trafficking of the coxsackie and adenovirus receptor. She received her BS in Life science from Ocean University of China.
Kendra joins Parthenon as an Associate Scientist II on the Tumor Biology team. She is excited about the opportunity to develop new therapies for patients with difficult to treat cancers. Prior to joining Parthenon, Kendra was a Senior Research Associate at Totus Medicines, where she supported the development of novel cell-based binding assays to screen potential covalent inhibitors of cancer targets. She received her BA in Environmental Science from Bennington College and discovered her passion for research while studying hydroid biodiversity and population connectivity in the Sargasso Sea with the Sea Education Association. In her free time, Kendra enjoys finding new activities and foods in the Boston area, spending time outside, and trying new crafts and creative pursuits.
Lauren joins Parthenon as the Head of Administration. Lauren has over 15 years of experience in the life sciences sector in various operations and administrative roles. Lauren works closely to support our CEO, Executive Team and the Board of Directors.

Lauren enjoys spending time making art with her husband, four children and taking care of her house plants and vegetable garden.

Jeff is Vice President and Head of Clinical Operations at Parthenon. He provides operational oversight for conduct of clinical trials mirroring Parthenon's mission, strategy, and corporate core values. He brings a wealth of clinical trial research experience to the Parthenon team through his 30 years in drug development, fulfilling leadership roles in project management, clinical operations, and line management. Throughout his career, Jeff has overseen multiple key CRO-Sponsor partnerships which included full-service clinical trials for early drug development, registrational and observational studies. Most recently he served as Oncology Global Therapeutic Head at Pharm-Olam and Sr. Director of IQVIA's largest late phase oncology client. He served for 24 years at ICON Clinical Research / PRA Health Sciences in various roles including Executive Director of Project Delivery and Business Unit Leader of the Americas Clinical Team Management Group.

Over the last 12 years, Jeff's primary focus has been in the management of oncology and hematology studies. His therapeutic expertise also includes cardiovascular, women's health, endocrinology, neurology, psychiatry, pediatric, rare disease, and anti-infective studies, receiving approvals for oncology, CNS, rare disease, anti-infective and cardiovascular compounds.

Jeff won the PRA President's Award twice and the PharmaTimes Clinical Researcher of the Year. He received his degree from Yale University in Neurobiology. Jeff remains passionate about developing new treatment options that address the unmet medical needs for cancer patients.

Prior to joining Parthenon as the Principal Scientist of Cancer Biology, Yan has over 10 years of experience in industry and academia. One of Yan's postdoctoral research published in Cell has a significant impact on advancing the mechanistic understanding of TGF-β signaling in the brain development, with an emphasis on microglia and immune function. She also played the key roles in conducting the preclinical studies on CTX-8371 to enable IND filing in Compass Therapeutics. Yan received postgraduate training at Harvard Medical School and Children's Hospital Boston in the laboratory of Dr. Timothy Springer and received a Ph. D from Chinese Academy of Sciences.
Prior to joining Parthenon as the Senior Scientist of Translational Biology, Susannah was a Postdoctoral Scholar at Novartis Institutes for Biomedical Research where she worked jointly between the Oncology and Immuno-Oncology departments. Her research studied the role of immunosuppressive immune cell receptors in the tumor microenvironment using Visium Spatial Gene Expression ® technology and single cell RNA-sequencing. She completed her PhD in 2017 at Weill Cornell Graduate School in Immunology and Microbial Pathogenesis. Her doctoral research studied the DNA repair mechanisms of the malaria parasite, Plasmodium falciparum using whole genome sequencing. She received her BA in Biology from Smith College in 2010.
Tom has nearly two decades of immunology experience and over 10 years of industry experience working on drug discovery programs focused on immuno-oncology and autoimmunity. Tom joins Parthenon from Omega Therapeutics where he was Director of Immunology where he led multiple drug discovery programs and managed a team of scientists. Previously, he has held positions at Pfizer where he worked on multiple large molecule programs, and at KSQ Therapeutics where he led the Biotherapeutics group. Tom received his PhD from the University of Minnesota and held postdoctoral positions at the National Institutes of Health and MedImmune.
Mark joins Parthenon with a diverse set of drug discovery experiences from his various leadership roles in academia, industry, and CRO organizations. Prior to joining Parthenon, Mark was the Global Head of Biology and site-head of the Boston Exploratory Biology Labs at Sai Life Sciences, a CRO supporting externalized drug discovery services. Mark's team supported clients' drug discovery screening programs with his Boston-based team primarily supporting exploratory projects, including target validation and development of novel biochemical and cell-based assays. Mark has extensive oncology discovery experience from past roles at Merck & Co., the Belfer Center at the Dana Farber Cancer Institute, and Agios Pharmaceuticals. Mark obtained his PhD at the University of Wisconsin-Madison and completed post-doctoral training at the McArdle Labs for Cancer Research and at Novartis Institutes for Biomedical Research.
Xinwei brings 15 years of bioinformatics/data science experience in pharmaceutical and biotech industry. Before joining Parthenon, Xinwei led a bioinformatic team in Constellation Pharmaceuticals focusing on data mining of tumor perturbation screening and multiomics for target identification and biomarker discoveries, and construction of bioinformatics data analysis capabilities. Prior to that, Xinwei spent 13 years of his career in Merck, where he played key data science roles in different stages of drug discovery pipelines, including target ID/validation, mode of action studies, vaccine design and large-scale clinical biomarker discoveries. Xinwei started his bioinformatics career as a postdoc fellow in Even Eichler's lab in University of Washington, Seattle, where he studied human genome evolution. He received Ph.D. in Immunology and M.S. in Computer Science from Roswell Park Cancer Institute/SUNY Buffalo.
Prior to joining Parthenon, Katherine received her PhD from Princeton University. Her work focused on how interactions between extracellular matrix proteins and heparan sulfate proteoglycans influence tissue fibrosis. Before performing her PhD work, she developed biomarkers for treatment of sarcoma patients at Beth Israel Deaconess Medical Center/Harvard Medical School. She received her BA in Biochemistry and Molecular Biology and English from Boston University.
Sue is Vice President, R&D Strategy & Program Management at Parthenon. She is an experienced biotech executive with more than 25 years of experience in research and development, spanning several therapeutic areas and therapeutic modalities. Her expertise includes basic and translational research, leading cross-functional discovery and development programs, developing strategies for projects and portfolios, and alliance management. She has deep experience in preparing and submitting INDs/CTAs, including meeting with regulatory agencies in North America and Europe, and in the development of strategies for programs through registration. She most recently served as Vice President of Research and Development at Aldeyra Therapeutics. Prior to joining Aldeyra, she held senior roles in R&D Strategy, Portfolio, and Project Management at Alexion Pharmaceuticals and Program Management at NKT Therapeutics. She has also served in a variety of roles at Archemix, ArQule, TEI Biosciences, and Onyx Pharmaceuticals, where, as a founding employee, she conducted research that enabled the discovery of sorafenib (Nexavar®). Sue also advises and helps emerging companies navigate the intersecting paths of strategy, science, and development.

Sue received her undergraduate degree in biology from Hobart and William Smith Colleges and her Ph.D. in Physiology from the University of Massachusetts Medical School. She completed her postdoctoral training at Onyx Pharmaceuticals, during which she received a prestigious NIH National Research Service Award.
Tamas brings nearly three decades of biotech and pharma R&D leadership experience to his role at Parthenon. His experience includes developing a broad range of therapeutic modalities including small molecules, antibody and cell therapy platforms and other biotherapeutic approaches, as well as leading and directing drug development programs from experimental research to INDs, including two drug approvals.

Tamas joins Parthenon from Janssen Biotherapeutics, a division of Johnson & Johnson, where most recently he served as Vice President, Head of Cell Therapy Platform and Discovery. During his tenure at Janssen, he led large, multidisciplinary teams of scientists to advance new therapeutic candidates in diverse disease areas from discovery into early development and proof of concept studies in humans. Previously, he was the Executive Director of Biology and Pharmacology at Celgene (acquired by Bristol-Myers Squibb Company) where he was responsible for building a world-class discovery team and contributing to the advancement of several of Celgene's small and large molecule programs. He is the inventor on numerous patents and patent applications and has published nearly 50 research papers and book chapters.
Laurent is co-founder, CEO & Chairman of Parthenon Therapeutics.
He has contributed to the identification and development of seven novel medicines (Xeljanz®, Hemangiol®, Javlor®, Renflexis®, Brenzys®, Ontruzant®, Hadlima® – biologics and small molecules) addressing unmet medical need across multiple disease areas that generate > $3B in annual sales.

Laurent has also led business and R&D functions in both pharma and biotech (US and EU), including CEO of Kymera Therapeutics, head of R&D with Pierre Fabre Pharmaceuticals, and positions of increasing leadership responsibilities on the business and science fronts at Pfizer, Merck, and Pieris contributing to the advancement of 21 drug candidates into clinical development across multiple disease areas and modalities. He has completed partnering transactions worth over $3B in biobucks and raised > $250M.

He studied chemistry and pharmacology (Ph.D.) at Vanderbilt University and completed postdoctoral training at UNC/Chapel Hill and Duke University where he was the recipient of an American Heart Association Fellowship. He has co-authored over 70 papers and patents. Laurent also serves as an independent director on the board of Cytovia, Ixaka, Ermium, and is a member of Ventus' scientific advisory board.
Laura Dillon is the Head of Translational Biomarkers, responsible for designing and implementing Parthenon's biomarker strategy. She has over 15 years of experience in industry, academia, and government. Prior to joining Parthenon, Laura was the Director of Pathology Data Strategy at AstraZeneca, focusing on the development of novel methodologies to extract information from imaging datasets and the implementation of non-invasive bioimaging techniques to advance the drug development pipeline. Laura has a Ph.D. in Bioinformatics and Genomics from the University of Maryland.
Glenn is a co-founder and Head of Discovery of Parthenon Therapeutics. Glenn is a hematologist/medical oncologist with over 20 years of clinical practice and drug development experience.

Prior to Parthenon, he's held positions of increasing scientific leadership responsibilities across the biotech industry (CEO of BioCurate, CSO of Xilio and TetraLogic, and NED at Oxford Biotherapeutics).

From 2002-2012, he was VP and Global Head of Hematology/Oncology Research at Amgen, California, responsible for 5 research sites; for supporting marketed products including the filgrastim and erythropoietin franchises (approx. US$4B pa and US$8B pa respectively). Over 25 clinical-stage molecules emerged from his group.

Glenn has highlighted the issue of research integrity and scientific reproducibility. He has made presentations on this subject including to President Obama's Science Council, the White House, US National Institutes of Health, US Academies of Science, US National Institute of Standards and Technology, Wellcome Trust, NHMRC, and numerous Universities, Research Institutes and companies.

His early research first described human G-CSF, then demonstrated that G-CSF-"mobilized" blood stem cells (so called "stem cell transplantation") hastened recovery versus bone marrow transplantation.

He was elected as the first Foreign Fellow to the American Society of Clinical Investigation (2000), the Association of American Physicians (2008), to the Research "Hall of Fame" at his alma mater, the Royal Melbourne Hospital (2014), to the Australian Academy of Health and Medical Sciences (2014). He has published over 200 papers (~25,000 citations; h-index 77; i10-index 188, source Google Scholar, August 2020). His TED-x seminar "The Complex Biology of Cancer" has >100,000 views.
Ibrahim joins Parthenon Therapeutics as an Associate Scientist II to study the tumor microenvironment. Previously, he was a research associate at Repertoire Immune Medicines where his work focused on developing therapies for autoimmune diseases. Before, he also held a research position at Dana-Farber Cancer Institute where he worked on adoptive cell therapies and chemotherapy resistance mechanisms in head and neck cancers. Ibrahim is excited by the novel opportunity to tackle cancers while learning about the cutting-edge science executed by the talented team at Parthenon.
Before joining Parthenon Therapeutics, Thomas was a Director of Discovery Biology and first scientist hired at Scholar Rock, Inc., a Cambridge biotechnology company that focuses on the discovery and development of novel growth factor-targeting antibodies for the treatment of musculoskeletal diseases, fibrosis, and cancer. During his nine year tenure at Scholar Rock, Thomas built up the company's TGFβ portfolio and led the discovery of SRK-181, a selective inhibitor of latent TGFβ1 activation that is currently being investigated in the DRAGON Phase 1 clinical trial in patients with locally advanced or metastatic solid tumors. He is an inventor on several granted patents and international patent applications. Thomas received postgraduate training at Harvard Medical School and Children's Hospital Boston in the laboratory of Dr. Timothy Springer and received a Ph.D from ETH Zurich, Switzerland.
Travis is a co-founder of Parthenon Therapeutics and the Head of Clinical Sciences. Travis is a practicing surgical oncologist and clinical trialist with over 13 years of oncology drug development and clinical practice experience.

He received a BS in Chemistry from the United States Military Academy at West Point and a medical degree from Vanderbilt University Medical School. He completed General Surgery residency at BAMC and Complex General Surgical Oncology fellowship at University of Texas MD Anderson Cancer Center. He has deployed multiple times overseas to combat zones and within the US for COVID-19 response with the US Army. He has 13 years of experience in translational cancer immunotherapy research with intimate experience with the design, initiation, and execution of cancer immunotherapy clinical trials. He has over 60 peer-reviewed oncology publications, over 120 published abstracts, and multiple book chapters.
Chi joins Parthenon as a Sr Scientist in the Tumor Microenvironment Team. He is passionate about discovering the dynamic interaction between tumor cells and other microenvironmental components. Chi has been involved in the oncology field for more than 10 years. His research interests range from genetic modeling, molecular mechanism, large-scale screening, metabolism, to experimental therapies. He received a BS in Biotechnology from Sun Yat-sen University in China, and a Ph.D. in Genetics from Tufts University in Boston, MA. When he is not at the bench, Chi enjoys skiing in the winter and kayaking in the summer.
Dr. Eder is Chief Medical Officer at Parthenon, bringing over 30 years of clinical experience at leading cancer research institutions as well as the pharmaceutical industry. Most recently, Dr. Eder was Clinical Director of the Early Drug Development Program as well as Professor at the Yale School of Medicine. From 2010 to 2012, Dr Eder was Medical Science Director, Disease Area Clinical Expert, Hematology, AstraZeneca, PLC as well as Associate Clinical Professor, Harvard Medical School, Boston, MA. Dr. Eder was Clinical Discovery Sr. Director, Oncology, AstraZeneca, PLC from 2009 to 2012, prior to which he was Medical Science Director at AstraZeneca. From 2005 to 2010, Dr. Eder was Associate Professor, Harvard Medical School and from 2003 to 2007 was Clinical Director, Clinical Research Center at the Dana-Farber Cancer Institute. He was Clinical Director, Experimental Therapeutics & Translational Pharmacology, Dana-Farber Harvard Cancer Center from 1998 to 2007, and was Assistant Professor, Harvard Medical School from 1988 to 2004. From 1985 to 1988 Dr. Eder was Instructor, Harvard Medical School. Dr. Eder was awarded his MD from Georgetown University School of Medicine.
Lisa is Head of Clinical Strategic Alliances, leading our partnerships and managing site relationships at Parthenon.

She brings over 25 years of oncology clinical research experience in academia and industry, leading and managing clinical trials operations and business processes within major National Cancer Institute-designated cancer centers. Most recently, Lisa served as the Executive Director of Clinical Research Administration at the Mount Sinai Tisch Cancer Institute. In this role, she was responsible for overall leadership and strategic direction of the Institute's clinical research operations. Prior to serving at Mount Sinai, she also held leadership positions at Vanderbilt-Ingram Cancer Center and Perlmutter Cancer Center. She previously held various positions at Eli Lilly, responsible for managing sites and driving the successful implementation of clinical trials.
Anneka joins as Administrative Assistant to the Leadership Team. Anneka studied English Literature at the University of San Diego. She comes to Parthenon with 12 years of corporate experience, most recently in the Boston area. She started her career in the utilities sector in Southern California and relocated to Boston to be closer to family.
CLINICAL AND SCIENTIFIC ADVISORY BOARDS
ADVISORY BOARDs
  • Professor and Robert A. Welch Distinguished University Chair in Chemistry
    Director, Texas Therapeutics Institute
    University of Texas Health Science Center at Houston
  • Assistant Professor of Medicine (Medical Oncology)
    Yale University School of Medicine
  • Professor Emeritus University of Paris School of Medicine
    Leader of Cancer Immunotherapy Group Cordeliers Research Center
  • Head of Precision Oncology at Gustave Roussy
    Head of Early Clinical Development and Sarcoma Unit at Institut Bergonié
  • Carol Ann & David D. Flanagan Professor
    Department of Biomedical Engineering
    Georgia Institute of Technology & Emory University
  • Research Fellow, Centre for Cancer Biology
    University of South Australia
  • Chair and the Ross Professor of Basic Science Research
    Department of Biochemistry & Molecular Medicine
    The George Washington University School of Medicine and Health Sciences
  • Vice-President, Head of External R&D and Strategic Alliances, Oncology,
    AstraZeneca
  • Associate Professor, Department of Biomedical Engineering
    University of Minnesota
  • Former Chief Medical Officer Pfizer
    Former Professor of Medicine and Ingram Professor of Cancer Research at Vanderbilt
    Independent Consultant
  • Grace Lansing Lambert Professor of Biomedical Science
    Director, Penn Vet Cancer Center
    Chair, Department of Biomedical Sciences
    University of Pennsylvania School of Veterinary Medicine
  • Professor, Department of Medicine (Hematology/Oncology)
    University of California San Francisco
    Early Phase Clinical Trials Unit
    Co-leader of the Center for BRCA Research
    Co-leader of the Molecular Oncology Program
BOARD OF DIRECTORS
Board of Directors
Our Investors
Our INVESTORS
Join the Fight
Join the Fight
Our team is always excited to talk about collaborations to bend the survival curve for patients.
Join the Fight
Join the Fight
Our team is always excited to talk about collaborations to bend the survival curve for patients.
© 2022 Parthenon Therapeutics Inc. All rights reserved.
40 Guest St.
Boston, MA 02135
617.870.3363